Immunotherapy of melanoma: the good news, the bad ones and what to do next
- 31 December 2003
- journal article
- editorial
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 13 (6) , 387-389
- https://doi.org/10.1016/j.semcancer.2003.09.002
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cellsSeminars in Cancer Biology, 2003
- Peptide vaccine trials for melanoma: preclinical background and clinical resultsSeminars in Cancer Biology, 2003
- Active-specific immunization against melanoma: Is the problem at the receiving end?Seminars in Cancer Biology, 2003
- Local delivery of poxvirus vaccines for melanomaSeminars in Cancer Biology, 2003
- Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®Seminars in Cancer Biology, 2003
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003
- Symposium on ’Nutrition in the post-genomic era’ Plenary session 4: Genetic variation and diet-related diseaseProceedings of the Nutrition Society, 2002
- Natural selection of tumor variants in the generation of “tumor escape” phenotypesNature Immunology, 2002
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002